Ocugen Shares Face Critical Test Amid Steep Decline

The investment case for Ocugen is under severe pressure as its stock experiences a dramatic downward spiral. With bearish investors aggressively betting on continued losses, company leadership prepares for a pivotal presentation that could determine the biotech firm’s near-term trajectory. The substantial selling pressure witnessed in recent weeks raises fundamental questions about whether current valuations reflect market panic or foreshadow more challenging conditions ahead.

Market data reveals concerning technical indicators for Ocugen. The stock currently trades at €0.98, significantly below its 50-day moving average of €1.28, highlighting persistent weakness. More alarmingly, short interest has climbed to approximately 20.76% of available shares, indicating substantial skepticism among market participants about the company’s prospects. Read more...